Odyssey Therapeutics, Inc. (ODTX)
Nasdaq · Healthcare · Biotechnology
$20.84+0.55%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $1.0B
- 52-week range
- $15.10 – $29.05
- 52-week change
- +26.25%
- EPS (trailing)
- −$7.55
- Next earnings
- Nov 5, 2026
About Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Headquarters: Boston, United States · 100 employees · odysseytx.com